Biofrontera Inc.: A Compelling Investment in Dermatology
September 9, 2025
Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
February 15, 2022
Related Post
-
-
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
August 18, 2025
-
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results
August 18, 2025
-
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
August 11, 2025